7171 FREDERICK BANTING, SAINT-LAURENT, A8
Announces Completion of Acquisition by XenoTherapeutics, Inc.
Shareholders Approve Acquisition
Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration
CSO Michael Zinda Resigns from Repare Therapeutics Inc.
Repare Therapeutics Enters Arrangement Agreement with XenoTherapeutics
Enters into Definitive Agreement to be Acquired
Repare Therapeutics Announces Phase 1 Trial Data for RP-1664
Provides Business Update and Reports Second Quarter 2025 Financial Results
Q3
Q2
Q1
FY 2024
FY 2023
Notice of Suspension of Duty to File Reports
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Merger Proxy Statement
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Notification Filed by a National Security Exchange
S-8 POS
Post-Effective Amendment to Registration Statement